Romanian pharmaceutical R&D project
INVEU-ICR-0064-2023 – Research, Innovation and Digitisation Window (RIDW)

Short description of the financing or investment operation and its objectives
Name of final recipient: Antibiotice S.A
Countries of implementation: Romania
Implementing partner: European Investment Bank (EIB)

It is intended to enhance the industrial as well as the research development and advanced manufacturing capabilities of the Company by investment into:

(i) advanced manufacturing capabilities for sterile products (topical and powder forms). This sub-project spans all project tasks from project design, procurement and contracting for purchasing European best-in-class manufacturing equipment and clean rooms, regulatory authorisations, good manufacturing practice and test-first batch production.

(ii) large Research and Development Centre, including purchasing the most advanced technology equipment and platforms, employment of dedicated personnel as well as the first feasibility steps for the development of the next generation of the Company’s portfolio products.

(iii) site digitalization and computerization activities at the manufacturing and operations sites.

Global Assessment and rationale for approval
The Investment Committee of the InvestEU Fund approved the use of the InvestEU guarantee on 12 October 2023 for the above-mentioned operation.

Under the Research, Innovation and Digitisation Window of InvestEU, the financing of this project addresses the failure in financial markets for RDI-driven Romanian SMEs and mid-caps suffering from systemic shortages of large, non-dilutive financing options for growth investments in life sciences which require a longer time horizon with inherently higher levels of risk. RDI is associated with externalities, ie. positive knowledge and technology externalities, through the creation of innovative processes, products and services and through skills development and upgrading, which the Company generally fails to internalize, leading to underinvestment.

The Project would not be carried out to the same extent without support from InvestEU. The EIB loan’s long tenor combined with flexible drawdown and repayment terms are instrumental to the successful implementation of the project. Expanding its activities, the EIB support will also enable the company to address the employment needs of a locally underserved population.
Conclusions

The Investment Committee welcomes this project in a strategic sector for Europe as a relevant initiative for EU cohesion region.